bilaterals.org logo
bilaterals.org logo

intellectual property


How capitalism and other viruses are ravaging the Global South
The economic hegemony exerted by the trade regime — and related financial structures — mirrors and extends old colonial patterns of exploitation and dispossession. Its policies represent our “normal.”
RIAA welcomes US-UK trade talks progress
Copyright protections between the two music markets were a vital part of any deal, the chairman and CEO of the Recording Industry Association of America (RIAA) said.
Union calls for equal recognition for healthcare workers
The union and its allies also asked the government not to join the Trans-Pacific Partnership, as they view that the restriction of rights to access medicine under the deal would put the country’s public health system in danger.
US firms give condition for free trade deal with Kenya
American firms have asked Kenya to fix its intellectual property laws as one of the conditions for backing the “model trade agreement” being negotiated by the two states.
India on US patent watch list
The US on Wednesday placed India on the “Priority Watch List” for the lack of sufficient measurable improvements to its intellectual property framework
Coronavirus: China yet to meet key phase one trade deal target due to Covid-19 lockdown
China was due to release intellectual property action plan 30 working days after phase one trade deal came into force on February 15.
The Comprehensive and Progressive Agreement for the Trans-Pacific Partnership: Data exclusivity and access to biologics
The agreement does not promise that the suspended provision on test data rule concerning biological medicines will remain suspended.
Intellectual property rights: Potential implications of the DCFTA for access to medicine
If the intellectual property provisions of the DCFTA are applied, this will have an impact on both the cost of patented medicines and undermine access to affordable medicines.
Regional MPs call for greater transparency of RCEP negotiations
As ministers of the member countries of the RCEP meet for final negotiations over the trade agreement this week, regional lawmakers today expressed concern about the lack of parliamentary and public oversight of the deal, as well as its potential human rights impacts.
Can a US-India trade deal permanently alter the way Indians access medicines?
US-India IP engagements since 2006 have served the interests of the US through systematic undermining of the legislative safeguards in the Indian Patents Act.
Civil society groups oppose India-US MoU on intellectual property rights
Civil society groups want the contents of the MoU to be made public before its finalisation to ensure that India resists US demands to influence the implementation of India’s IP legislations.
India, US ink pact on intellectual property rights
India and the US have signed an agreement on intellectual property rights (IPR) ahead of US President Donald Trump’s visit. The Cabinet Wednesday approved an MoU with the US on the issue of IPRs.
A new approach on investment
A US-India trade deal will have historic significance, especially if it ushers in a period of strong collaboration to advance a shared bilateral trade agenda and effectively resolves troubles as they arise.
Phase 1 US China trade deal: patent provisions
China agreed to extend patent terms for novel drugs "to compensate for unreasonable delays that occur in granting the patent or during pharmaceutical product marketing approvals."
Blueprint for a human rights impact assessment of the planned comprehensive free trade agreement between EFTA and Mercosur
This study assesses the impact of the EFTA-Mercosur free trade agreement on access to medicines, indigenous rights and women rights.
Big Pharma looks to stem losses after trade deal defeat
The industry is working to get US senators on record in support of including the protections it lost in NAFTA 2.0 in future trade agreements with other countries.
India’s withdrawal from RCEP a breather on many fronts
India’s decision to pull out of RCEP means its policy on access to inexpensive drugs will not be under pressure.
China’s new policy on foreign investment and the security of intellectual property
Proper mandatory licenses will be exempt from claims for expropriation under the China BIT model.
What the amendments to the USMCA mean for Canadian IP law
Many requirements of the original USMCA have already been met by recent changes in Canadian IP legislation, but more amendments will be required to implement the USMCA.
Phase two of US-China trade deal will be more challenging and less transparent than phase one
The hard part of the trade dispute will cover long-standing issues relating to intellectual property violations and forced technology transfer by China, as well as subsidization of Chinese industries.